LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02649764

LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The goal of this clinical research study is to study the safety of LY2606368 when given in combination with fludarabine and cytarabine. The effectiveness of the study drug combination when given to patients with relapsed or refractory AML or HRMDS will also be studied.

Status: 
Not yet recruiting
Study Date: 
Sat, 04/30/2016 to Thu, 04/01/2021
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: Fludarabine Induction and Consolidation Phase Dose of Fludarabine: 30 mg/m2 by vein over 2 hours for 4 days. Other Names: Fludarabine Phosphate Fludara Drug: Cytarabine Induction and Consolidation Phase Dose of Cytarabine: 1.5 gram/m2 continuous infusion daily for 4 days. Other Names: Ara-C Cytosar DepoCyt Cytosine Arabinosine Hydrochloride Drug: LY2606368 Induction Phase Starting Dose of LY2606368: 30 mg/m2 by vein daily for 3 days (days 1, 3, 4). Consolidation Phase Starting Dose of LY2606368: Maximum tolerated dose (MTD) from Induction Phase.